Dr Huppert on Sequential Treatment with T-DXd and Sacituzumab Govitecan in HER2-Low Breast Cancer

Laura A. Huppert, MD, discusses the impact of sequential treatment with fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy on outcomes in patients with HER2-low metastatic breast cancer, according to findings from a retrospective analysis.

Related Keywords

San Francisco ,California ,United States , ,University Of California ,San Francisco School Of Medicine ,San Francisco School ,Ucsf ,T Dxd ,Sacituzumab Govitecan Hziy ,Fam Trastuzumab Deruxtecan Nxki ,Her2 Low Metastatic Breast Cancer ,